These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

296 related articles for article (PubMed ID: 36294361)

  • 1. Lipoprotein(a): Evidence for Role as a Causal Risk Factor in Cardiovascular Disease and Emerging Therapies.
    Bhatia HS; Wilkinson MJ
    J Clin Med; 2022 Oct; 11(20):. PubMed ID: 36294361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Oxidized phospholipids as a unifying theory for lipoprotein(a) and cardiovascular disease.
    Boffa MB; Koschinsky ML
    Nat Rev Cardiol; 2019 May; 16(5):305-318. PubMed ID: 30675027
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Lipoprotein(a) in atherosclerotic cardiovascular disease and aortic stenosis: a European Atherosclerosis Society consensus statement.
    Kronenberg F; Mora S; Stroes ESG; Ference BA; Arsenault BJ; Berglund L; Dweck MR; Koschinsky M; Lambert G; Mach F; McNeal CJ; Moriarty PM; Natarajan P; Nordestgaard BG; Parhofer KG; Virani SS; von Eckardstein A; Watts GF; Stock JK; Ray KK; Tokgözoğlu LS; Catapano AL
    Eur Heart J; 2022 Oct; 43(39):3925-3946. PubMed ID: 36036785
    [TBL] [Abstract][Full Text] [Related]  

  • 4. New Frontiers in Lp(a)-Targeted Therapies.
    Borrelli MJ; Youssef A; Boffa MB; Koschinsky ML
    Trends Pharmacol Sci; 2019 Mar; 40(3):212-225. PubMed ID: 30732864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Elevated Lp(a): Guidance for Identifying and Managing Patients.
    Hilleman DE; Vacek JL; Backes JM
    South Med J; 2024 Apr; 117(4):208-213. PubMed ID: 38569611
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lipoprotein(a): Expanding our knowledge of aortic valve narrowing.
    Youssef A; Clark JR; Koschinsky ML; Boffa MB
    Trends Cardiovasc Med; 2021 Jul; 31(5):305-311. PubMed ID: 32525013
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lipoprotein(a): Emerging insights and therapeutics.
    Kaur G; Abdelrahman K; Berman AN; Biery DW; Shiyovich A; Huck D; Garshick M; Blankstein R; Weber B
    Am J Prev Cardiol; 2024 Jun; 18():100641. PubMed ID: 38646022
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lipoprotein(a) and calcific aortic valve stenosis: A systematic review.
    Guddeti RR; Patil S; Ahmed A; Sharma A; Aboeata A; Lavie CJ; Alla VM
    Prog Cardiovasc Dis; 2020; 63(4):496-502. PubMed ID: 32526213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Is Lipoprotein(a) Clinically Actionable with Today's Evidence? The Answer is Yes.
    Ma GS; Chiou TT; Wilkinson MJ
    Curr Cardiol Rep; 2023 Oct; 25(10):1175-1187. PubMed ID: 37632608
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lipoprotein(a) and its Significance in Cardiovascular Disease: A Review.
    Duarte Lau F; Giugliano RP
    JAMA Cardiol; 2022 Jul; 7(7):760-769. PubMed ID: 35583875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High lipoprotein(a): Actionable strategies for risk assessment and mitigation.
    Reyes-Soffer G; Yeang C; Michos ED; Boatwright W; Ballantyne CM
    Am J Prev Cardiol; 2024 Jun; 18():100651. PubMed ID: 38646021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. What is the ultimate test that lowering lipoprotein(a) is beneficial for cardiovascular disease and aortic stenosis?
    Hung MY; Tsimikas S
    Curr Opin Lipidol; 2014 Dec; 25(6):423-30. PubMed ID: 25340480
    [TBL] [Abstract][Full Text] [Related]  

  • 13. NHLBI Working Group Recommendations to Reduce Lipoprotein(a)-Mediated Risk of Cardiovascular Disease and Aortic Stenosis.
    Tsimikas S; Fazio S; Ferdinand KC; Ginsberg HN; Koschinsky ML; Marcovina SM; Moriarty PM; Rader DJ; Remaley AT; Reyes-Soffer G; Santos RD; Thanassoulis G; Witztum JL; Danthi S; Olive M; Liu L
    J Am Coll Cardiol; 2018 Jan; 71(2):177-192. PubMed ID: 29325642
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pathobiology of Lp(a) in calcific aortic valve disease.
    Mathieu P; Arsenault BJ; Boulanger MC; Bossé Y; Koschinsky ML
    Expert Rev Cardiovasc Ther; 2017 Oct; 15(10):797-807. PubMed ID: 28816078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Daring to dream: Targeting lipoprotein(a) as a causal and risk-enhancing factor.
    Koschinsky ML; Stroes ESG; Kronenberg F
    Pharmacol Res; 2023 Aug; 194():106843. PubMed ID: 37406784
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular, Population, and Clinical Aspects of Lipoprotein(a): A Bridge Too Far?
    Ward NC; Kostner KM; Sullivan DR; Nestel P; Watts GF
    J Clin Med; 2019 Nov; 8(12):. PubMed ID: 31783529
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Experimental Animal Models Evaluating the Causal Role of Lipoprotein(a) in Atherosclerosis and Aortic Stenosis.
    Yeang C; Cotter B; Tsimikas S
    Cardiovasc Drugs Ther; 2016 Feb; 30(1):75-85. PubMed ID: 26780907
    [TBL] [Abstract][Full Text] [Related]  

  • 18. To test, or not to test: that is the question for the future of lipoprotein(a).
    Ellis KL; Chakraborty A; Moses EK; Watts GF
    Expert Rev Cardiovasc Ther; 2019 Apr; 17(4):241-250. PubMed ID: 30916582
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Test in Context: Lipoprotein(a): Diagnosis, Prognosis, Controversies, and Emerging Therapies.
    Tsimikas S
    J Am Coll Cardiol; 2017 Feb; 69(6):692-711. PubMed ID: 28183512
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Lp(a) and risk of cardiovascular disease - A review of existing evidence and emerging concepts.
    Jasti M; Islam S; Steele N; Ivy K; Maimo W; Isiadinso I
    J Natl Med Assoc; 2023 Dec; ():. PubMed ID: 38143155
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.